4-(噻吩-3-基)哌啶 | 291289-51-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-(噻吩-3-基)哌啶
• 英文名称: 4-(thiophen-3-yl)piperidine
• 英文别名: 4-thiophen-3-ylpiperidine
• CAS: 291289-51-5
• 化学式: C₉H₁₃NS
• mdl: MFCD17485220
• 分子量: 167.275
• InChiKey: KTOGEYCNOXECIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  40.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(噻吩-3-基)哌啶 、 (2S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluorophenyl)-4-oxobutanamide 在 4 A molecular sieve 、 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 (S)-N-(3,5-Bis-trifluoromethyl-benzyl)-2-(4-fluoro-phenyl)-4-(4-thiophen-3-yl-piperidin-1-yl)-butyramide
  参考文献：
  名称：

  Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists

  摘要：

  Through modification of a screening hit we have discovered a structurally distinct new lead, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(4-phenylpiperidin-1-yl)butanamide (11), which has subsequently served as the departure point for an ongoing program targeting CCR2 antagonists. Optimization of 11 leading to antagonists 26 and 37 is described. Antagonist 26 was shown to have good oral bioavailability in rats. Antagonist 37 had a CCR2 IC50 of 59 nM and excellent potency in a functional assay measuring inhibition of MCP-1 induced monocyte chemotaxis (IC50 of 41 nM).

  DOI：

  10.1021/jm060439n

文献信息

• Compounds useful for inhibiting metastasis from cancer and methods using same
  申请人：Drexel University

  公开号：US10414771B2

  公开（公告）日：2019-09-17

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.

  本发明包括可用于预防或治疗确诊癌症患者转移的组合物。本发明还包括预防或治疗被诊断患有癌症的受试者的转移的方法，其中该方法包括向需要该方法的受试者施用有效量的药物制剂，该药物制剂包含至少一种药学上可接受的载体和至少一种CX3CR1或fractalkine拮抗剂。
• Aromatisch substituierte Azacyclo-alkylalkandiphosphonsäuren
  申请人：CIBA-GEIGY AG

  公开号：EP0272208B1

  公开（公告）日：1991-06-12
• Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same
  申请人：Drexel University

  公开号：US20180099972A1

  公开（公告）日：2018-04-12

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.
• US4871720A
  申请人：——

  公开号：US4871720A

  公开（公告）日：1989-10-03
• US7247725B2
  申请人：——

  公开号：US7247725B2

  公开（公告）日：2007-07-24